Mr. Shaun Flanagan:

No, there are multiple scenarios where that happens. That is not a criticism of the process undertaken by the NCPE. It looks at a medicine at a priming point, at a price at that point and gives advice. Professor Barry is always very clear in the media that what he is giving is advice on the basis of the proposition put forward by the company. Is it a reasonable use of money at that time? If we can improve the commercial terms, clearly the reality is for almost every medicine 20% to 25%, 30% to 35% is how the terms move. That is how the prices move over time. That is a substantively different matter to the that Professor Barry would have been asked to look at.